Ir para o conteúdo principal
Immutep reports 81.1% 12-month disease-free survival in sarcoma trial
Image for illustrative purposes only. Not a real photo.

Immutep reports 81.1% 12-month disease-free survival in sarcoma trial

Por

Pontos principais

  • Immutep reported an estimated 81.1% disease-free survival rate at 12 months in its Phase II EFTISARC-NEO trial evaluating eftilagimod alfa with pembrolizumab and radiotherapy in patients with high-risk, resectable soft tissue sarcoma.
  • Eight of the 38 patients who underwent surgery experienced disease recurrence by April 30, 2026. The estimated 18-month disease-free survival rate also stood at 81.1%, although the data remain immature.
  • Immutep is targeting the second half of 2027 to begin a registration-intended clinical trial, with additional EFTISARC-NEO data expected in 2027.

Immutep (NASDAQ:IMMP) reported encouraging survival results from its Phase II EFTISARC-NEO trial, with an estimated 81.1% disease-free survival rate at 12 months among patients with high-risk, resectable soft tissue sarcoma.

The study evaluated eftilagimod alfa (efti) in combination with pembrolizumab and radiotherapy before surgery.

Of the 40 patients enrolled, 38 underwent surgery and were included in the survival analysis.

Eight patients had experienced disease recurrence as of April 30, 2026.

"The results are highly encouraging for patients with high-risk soft tissue sarcoma, where recurrence remains a major concern despite surgery and radiotherapy," said Pawel Sobczuk, one of the principal investigators of EFTISARC-NEO.

The estimated 18-month disease-free survival rate also stood at 81.1%, although the result remains immature and follow-up is ongoing.

The study additionally recorded 12-month local recurrence-free survival of 94.1% and distant metastasis-free survival of 86.2%.

Exploratory analyses found that patients with post-treatment tumour-infiltrating lymphocyte levels above 310 cells per square millimetre had 95% disease-free survival at 12 months, compared with 64.9% among those with lower levels.

Patients with treatment-related tumour hyalinisation and fibrosis above 52% recorded 93.8% disease-free survival, compared with 71.4% for those with lower levels.

The findings build on the trial's previously reported achievement of its primary endpoint, with median tumour hyalinisation and fibrosis reaching 51.5%, above the predefined target of 35%.

These changes indicate treatment-related alterations in tumour tissue following the preoperative combination therapy.

Immutep expects to report additional EFTISARC-NEO data in 2027 and is preparing a registration-directed clinical trial, targeting initiation in the second half of 2027.

The timeline remains subject to regulatory discussions, manufacturing arrangements, potential partnerships and available resources.


Perguntas frequentes